



NOW AVAILABLE

cPass™ SARS-CoV-2 Neutralization Antibody Test

SPECIFIC DETECTION OF SARS-CoV-2 NEUTRALIZING ANTIBODIES

Rapid Assessment of Immune Response to Today's Vaccines

- ✓ The cPass™ SARS-CoV-2 Neutralization Antibody Test is first and only antibody test with FDA Emergency Use Authorization (EUA) to specifically detect neutralizing antibodies.
- ✓ Blood test offers fast detection of neutralizing antibodies produced in response to vaccination or previous SARS-CoV-2 infection.
- ✓ Results are available within 24 hours of lab receipt.
- ✓ Neutralizing antibody testing is advised after at least 7 days from known previous infection or 6 weeks after initial vaccination. Routine serial testing is also recommended for monitoring vaccine response and potential need for further immunization.
- ✓ A Positive or Negative result for SARS-CoV-2 neutralizing antibodies can aid health care providers with immunization decisions and assessment of appropriate timing required between doses or boosters.
- ✓ The test uses ELISA technology to specifically detect neutralizing antibodies to the receptor binding domain (RBD) of the spike protein of SARS-CoV-2.



HOW DO NEUTRALIZING ANTIBODIES PROTECT AGAINST COVID-19?

- Neutralizing antibodies may be produced by the body in response to vaccination or previous SARS-CoV-2 infection.
- These antibodies attach to the RBD of the spike protein that facilitates entry of the virus into human cells.
- When neutralizing antibodies are attached to the RBD of the spike protein, the virus is blocked from entering by preventing the association with the ACE2 receptor on the human cell, thereby preventing infection.

Please contact www.biodesix.com/contact-covid or covidtesting@biodesix.com for more information

1. Baden, et al. "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine." N Engl J Med 2021; 384:403-416; DOI: 10.1056/NEJMoa2035389. 2. Polack, et al. "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine." N Engl J Med 2020; 383:2603-2615; DOI: 10.1056/NEJMoa2034577 3. Sadoff, et al. "Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19." Epub ahead of print. April 21, 2021; DOI: 10.1056/NEJMoa2101544 4. Tan, Chee Wah, et al. "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction." Nature biotechnology 38 (2020): 1073-1078. 5. Taylor, Sean C., et al. "A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection." Journal of Clinical Microbiology 59 (2021). ©2021 Biodesix. All rights reserved. CVD21000